Exam 3 - Diabetes Part 3 Non-Insulin Treatments Flashcards
metformin off-label uses (2 of them)
-T1DM pts who are overweight and have low risk of ketoacidosis
-PCOS (lowers androgen, inc ovulation)
metformin drops A1C by ___-___% and FBG by ___-___ mg/dL
1.5-2%
60-80 mg/dL
metformin decreases TG and LDL by ___-___%
8-15%
metformin disadvantage: it can cause _____ _____
lactic acidosis
avoid metformin in pt at risk for lactic acidosis. What are the risk factors? (5 of them)
-post MI
-COPD
-hepatic failure
-shock
-surgery/radiologic procedure with contrast dye
how long should metformin be held in pts with surgery/radiologic procedure with contrast dye?
1-2 days before and then ~2 days after depending upon pt status
how often should metformin be titrated?
weekly or bi-monthly and inc by 250-500 mg/day
why was SA metformin recalled in May/June 2020?
due to levels of N-ntrosodimethhylamine (NDMA) above acceptable levels; NDMA can inc risk of cancer and liver damage
metformin dosing if eGFR is 60 or more
no renal CI to metformin, monitor SCr annually
metformin dosing if eGFR is > 45 and < 60
safe to use, continue use if already taking; monitor SCr every 3-6 months
metformin dosing if eGFR is 30-45
starting metformin not recommended; reduce metformin dose by 50% if already taking; monitor SCr every 3 months
metformin dosing if eGFR < 30
don’t start; stop metformin if currently taking
SGLT2’s efficacy:
dec A1C ___-___%
dec FBG ___-___ mg/dL
dec PPG ___-___ mg/dL
dec weight ___-___ kg
dec SBP ___-___ mmHg and dec DBP ___-___ mmHg
A1C: 0.5-1.0%
FBG: 25-35 mg/dL
PPG: 40-60 mg/dL
weight: 1-5 kg
SBP: 3-6 mmHg, DBP: 2-3 mmHg
PK of SGLT2’s: undergoes __________ to inactive metabolites
glucuronidation
hold SGLT2 ___ days before surgery (___ if on ertugliflozin)
3; 4
there is an FDA warning for bone fractures and dec BMD in pts taking which SGLT2?
a. dapagliflozin
b. ertugliflozin
c. canagliflozin
d. empagliflozin
c. canagliflozin
(Invokana)
there is an FDA warning for AKI for which TWO SGLT2s?
a. dapagliflozin
b. ertugliflozin
c. canagliflozin
d. empagliflozin
a. dapagliflozin
c. canagliflozin
which SGLT2 had an FDA warning for inc risk of leg and foot amputations, which was removed in 2020?
a. dapagliflozin
b. ertugliflozin
c. canagliflozin
d. empagliflozin
c. canagliflozin
(Invokana)
all SGLT2s have an FDA warning for serious genital infections, such as necrotizing fasciitis of the perineum, also known as what?
Fournier’s gangrene
canagliflozin dosing if eGFR > 60
100 mg daily
max dosing for canagliflozin if eGFR > 60
300 mg/day
canagliflozin max daily dose if eGFR 30-60
max 100 mg daily if no albuminuria
dapagliflozin dosing if eGFR > 45
5 mg daily
dapagliflozin max daily dose if eGFR > 45
max 10 mg daily
empagliflozin dosing if eGFR > 30
10 mg daily
empagliflozin max daily dose if eGFR > 45
max 25 mg daily